2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphodiesterase (PDE)
  5. PDE11 Isoform

PDE11

PDE11A (phosphodiesterase 11A) is a dual-specificity cyclic nucleotide phosphodiesterase that hydrolyzes both cAMP and cGMP, thereby regulating second-messenger signaling and controlling the amplitude of downstream PKA- and cGMP-dependent pathways[1][2]. PDE11A participates in cellular signaling networks that govern endocrine function, metabolism, and tissue-specific physiological responses through modulation of intracellular cyclic nucleotide turnover[1][3]. Mechanistically, PDE11A contributes to the regulation of cAMP/cGMP signaling cascades, which influence transcriptional programs and cellular homeostasis across multiple organs[3][4]. In disease contexts, genetic defects and loss-of-function variants in PDE11A have been associated with adrenocortical disorders, including primary pigmented nodular adrenocortical disease, isolated micronodular adrenocortical disease, adrenocortical hyperplasia, and Cushing syndrome-related phenotypes, supporting a role for disrupted cyclic nucleotide signaling in adrenal tumorigenesis[1][3][5]. Experimental and pathological studies further demonstrate broad tissue expression of PDE11A, with particularly high expression reported in the prostate and detectable expression in adrenal, testicular, renal, hepatic, pancreatic, pituitary, and skeletal muscle tissues[3][5]. Compared with related phosphodiesterase isoforms, PDE11A displays distinct biochemical properties, limited sequence similarity to other PDE families, and four splice variants with tissue-specific expression patterns, highlighting unique regulatory functions that cannot be directly inferred from other dual-substrate PDEs[2][3][6]. For experimental applications, PDE11A-selective inhibitors such as BC11-38 have been developed as research tools to investigate PDE11A-dependent signaling and evaluate its potential as a therapeutic target in endocrine and neurobiological disease models[6][8].

PDE11 Related Products (12):

Cat. No. Product Name Effect Purity
  • HY-111371
    PF-05180999
    		Inhibitor 99.96%
    PF-05180999 (PF-999) is a phosphodiesterase 2A (PDE2A) inhibitor, with an IC50 of 1.6 nM.
  • HY-108618
    BC11-38
    		Inhibitor 99.42%
    BC11-38 is a potent, selective, and biologically active PDE11 inhibitor, with IC50s of 0.28 µM and >100 µM for PDE11 and PDE1-10, respectively. BC11-38 elevates cAMP levels, PKA-mediated ATF-1 phosphorylation, and cortisol production in H295R cells.
  • HY-120741
    PF-04822163
    		Inhibitor
    PF-04822163 is an orally active, selective, and blood-brain barrier permeable PDE1 inhibitor with IC50 values of 2 nM, 2.4 nM, and 7 nM for PDE1A, PDE1B, and PDE1C respectively. PF-04822163 can be used in the research of attention deficit hyperactivity disorder or Parkinson's disease.
  • HY-116808B
    TPN729MA
    		Inhibitor 99.45%
    TPN729MA (TPN729 maleate) is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC50 value of 2.28 nM. TPN729MA affects erectile function and it can be used for the research of erectile dysfunction.
  • HY-116808
    TPN729
    		Inhibitor
    TPN729 is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC50 value of 2.28 nM. TPN729 affects erectile function and it can be used for the research of erectile dysfunction.
  • HY-181589
    PDE11A4-IN-2
    		Inhibitor
    PDE11A4-IN-2 is a selective PDE11A4 inhibitor with an IC50 of 33 nM. PDE11A4-IN-2 functionally inhibits PDE11A4-mediated catalytic activities of cAMP and cGMP in cellular models. PDE11A4-IN-2 is applicable to the research of age-related cognitive decline.
  • HY-181088
    PDE3/4-IN-4
    		Inhibitor
    PDE3/4-IN-4 is an orally active PDE3A and PDE4B inhibitor with IC50 values of 10 nM and 9.4 nM, respectively. PDE3/4-IN-4 shows selective activity relative to most other PDE family members. PDE3/4-IN-4 modulates the cAMP/PKA/CREB signaling pathway. PDE3/4-IN-4 inhibits pro-inflammatory factor IL-6. PDE3/4-IN-4 reduces expression of inflammatory markers in liver tissue. PDE3/4-IN-4 attenuates liver fibrosis. PDE3/4-IN-4 limits liver damage in cholestatic and sepsis-induced liver disease mice models. PDE3/4-IN-4 can be used for the research of liver injury, cholestatic liver diseases, sepsis-induced liver injury.
  • HY-181774
    PDE4/5-IN-1
    		Inhibitor
    PDE4/5-IN-1 is a selective phosphodiesterase 4/5 (PDE4/5) dual inhibitor. PDE4/5-IN-1 functionally inhibits PDE5, PDE4B2, and PDE4D2 activity. PDE4/5-IN-1 relaxes isolated rat prostate tissue, enhances nitric oxide-induced relaxation in isolated rat prostate tissue, and reduces alpha-1 adrenoceptor-mediated contractile responses in isolated rat prostate tissue. PDE4/5-IN-1 inhibits proliferation of human hyperplastic prostate cells. PDE4/5-IN-1 can be used for the research of benign prostatic hyperplasia.
  • HY-128234
    PDE11-IN-1
    		Inhibitor 98.23%
    PDE11-IN-1 is a PDE11 inhibitor and can be used for adrenal insufficiency research.
  • HY-156434
    PDE11A4-IN-1
    		Inhibitor
    PDE11A4-IN-1 (compound 23b) is a potent and selective PDE11A4 inhibitor with an IC50 of 12 nM. PDE11A4-IN-1 show high selectivity for PDE11A4 over PDE1, PDE2, PDE7, PDE8, and PDE9.
  • HY-170435
    PDE5-IN-13
    		Inhibitor
    PDE5-IN-13 (Compound 14b) inhibits phosphodiesterase 5 (PDE5A) with an IC50 of 3 nM. PDE5-IN-13 is a potential candidate for PAH (pulmonary arterial hypertension) research. PDE5-IN-13 has high selectivity for targets over PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. PDE5-IN-13 is orally active.
  • HY-10568
    TC-E 5005
    		Inhibitor
    TC-E 5005 is a potent and selective PDE10A inhibitor with IC50 values of 7.28, 239, 779, 919, 3,100, and 3,700 nM for PDE10A, 2A, 11A, 5A, 7B and 3A, respectively. TC-E 5005 inhibits adrenergic and neurogenic smooth muscle contractions in the human prostate.